Investigation reveals cytotoxic effects of rhodium complexes in tumor cells, indicating their potential in cancer therapy.
The effect of substituents in pyrazolylpyrimidine ligands and their rhodium(III) complexes with regard to their structures and properties was investigated. Complexation of 2‐(3,5‐dimethyl‐1 H ‐pyrazol‐1‐yl)‐4,6‐diphenylpyrimidine (HL Me ) and 2‐(3,5‐diphenyl‐1 H ‐pyrazol‐1‐yl)‐4,6‐diphenylpyrimidine (HL Ph ) with RhCl 3 gives two complexes, [RhL Me (H 2 O)Cl 2 ][RhL Me (EtOH)Cl 2 ]∙EtOH ( 1 ) and [RhL Ph (H 2 O)Cl 2 ] 0.49 [RhL Ph (EtOH)Cl 2 ] 0.51 ∙0.5EtOH. The substituents in the pyrazole ring of the ligand molecules affect the emission properties and cytotoxicity of the complexes. The [RhL Ph (H 2 O)Cl 2 ] 0.49 [RhL Ph (EtOH)Cl 2 ] 0.51 ∙0.5EtOH complex emits in the solid state at room temperature and at 77 K, while [RhL Me (H 2 O)Cl 2 ][RhL Me (EtOH)Cl 2 ]∙EtOH emits only at 77 K. The complexes reveal significant differences in cytotoxic activity: while [RhL Ph (H 2 O)Cl 2 ] 0.49 [RhL Ph (EtOH)Cl 2 ] 0.51 ∙0.5EtOH is low‐toxic against tumor Hep2 cells and non‐tumor MRC5 cells, [RhL Me (H 2 O)Cl 2 ][RhL Me (EtOH)Cl 2 ]∙EtOH exhibits more pronounced toxicity against both cell lines.
No takes yet. Share an insight, caveat, or question.
Bautina et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: